Attorney Docket No.: 01850 3-000840US Client Ref. No.: COCA 011-3 US

Inventor 3

Signature:

Inventor 4

Signature:

PTO/SB/01A (10-01)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION **USING AN APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	NOVEL METHODS OF DIAGNOSIS OF METASTATIC COLORECTAL CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF METASTATIC COLORECTAL CANCER					
As the below named inventor(s), I/we declare that:						
This declaration is directed to:						
Г		The attached application, or				
	\boxtimes	Application No. 10/087,080 filed on February 27, 2002				
		as amended on (if applicable);				
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;						
I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;						
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.						
All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.						
FULL NAME OF INVENTOR(S)						
Inventor 1	Sanfor	rd D. Markowitz Date: 10/15/02				
Signature:	5'4	Ly De Market Citizen of: U.S.A.				
Inventor 2		Date:				
Signature:	Citizen of:					

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Additional inventors are being named on form(s) attached hereto.

Date:

Date:

Citizen of:

Citizen of:



Attorney Docket No.: 01850 00840US Client Ref. No.: CaCA 011-3 US

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	NOVEL METHODS OF DIAGNOSIS OF METASTATIC COLORECTAL CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF METASTATIC COLORECTAL CANCER					
As the below named inventor(s), I/we declare that:						
This declaration is directed to:						
I		The attached application,	or			
I	\boxtimes	Application No. 10/087,0	30 filed on February 27, 20	002		
		as amended on	_ (if applicable);			
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;						
I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;						
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.						
All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.						
FULL NAME OF INVENTOR(S)						
Inventor 1		H. Mack	Date:	918/02		
Signature:	-6	- Huch	Citizen of: United S	States		
Inventor 2	Sanfo	rd David Markowitz	Date:			
Signature:			Citizen of:United S	States		
Inventor 3	Date:					
Signature:			Citizen of:			
Inventor 4			Date:			
Signature:	Citizen of:					

Additional inventors are being named on form(s) attached hereto.

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the purcent nour statement: This collection or information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.